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Background and Objectives: Advanced invasive thymomas are not
usually manageable by surgical resection and radiotherapy. We
reviewed our experience with a multidisciplinary approach and
evaluated chemotherapy in the treatment of invasive thymoma.
Patients and Methods: Seventeen consecutive patients with inva-
sive thymoma were treated with multimodality therapy consisting of
chemotherapy, surgery, and/or radiotherapy. Four patients had stage
III disease with superior vena cava invasion, nine had stage IVa
disease, and four had stage IVb disease. The chemotherapy regimen
consisted of cisplatin, doxorubicin, and methylprednisolone (CAMP).
Chemotherapy was administered in a neoadjuvant setting to the 14
patients and in an adjuvant setting to the remaining three patients.
Surgical resection was intended in all patients. After those treat-
ments, chemotherapy and/or radiation therapy were performed.
Results: All but one of the 14 patients with induction chemotherapy
responded to the CAMP therapy, and the response rate was 92.9%.
Seven of these patients underwent complete remission after surgical
resection and chemoradiotherapy, and the others underwent partial
remission. All three patients treated with surgical resection and then
chemotherapy with or without radiotherapy also achieved complete
remission. Tumor progression after multimodality therapy occurred
in 10 patients. After retreatment, eight of these patients were alive at
the time of analysis, with a median survival time after recurrence of
30 months. The 5- and 10-year overall survival rates for all patients
were both 80.7%. The major side effect of CAMP therapy was
acceptable neutropenia.
Conclusions: CAMP therapy was highly effective for invasive
thymomas, and the multimodality therapy containing this chemo-
therapy brought about good disease control in the majority of
patients. We believe that this multidisciplinary treatment with
CAMP therapy, surgery, and radiotherapy is a justifiable initial
treatment for patients with advanced invasive thymoma. Further-
more, appropriate treatments are essential for the long-term survival
of patients with recurrences after multimodality therapy.
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In patients with thymoma, surgical resection with or withoutradiation therapy has been advocated as the treatment of
choice for early-stage diseases.1–3 Nevertheless, advanced-
stage diseases such as tumors with great vessel invasion,
pleural and/or pericardial dissemination, lymph node involve-
ments, or distant metastases are difficult to manage by sur-
gery and radiotherapy, and the treatment strategy for those
diseases remains controversial.4,5
Chemotherapy has been shown to have significant antitu-
mor activity against unresectable, recurrent, or metastatic thy-
momas.6–9 Recently, multimodality therapy using chemother-
apy has been examined in the treatment of advanced
thymomas.10–12 Investigators have demonstrated that com-
bined-modality therapy can improve outcomes for advanced
thymoma patients. Nevertheless, the chemotherapy regimens
and treatment schedules in these studies were varied, and an
optimal treatment strategy has not yet been determined.
Furthermore, although it is well known that thymoma has a
slow-growing nature and a late recurrent tendency, few re-
ports contained longer follow-up data or results of retreat-
ment of recurrences.13–15
To improve the outcome of patients with advanced
invasive thymomas, we have conducted a study of multimo-
dality therapy including chemotherapy. Here, we report the
results with a longer follow-up.
PATIENTS AND METHODS
From February 1988 to September 2003, 38 patients with
thymoma were referred to our hospital. Their clinical character-
istics are shown in Table 1. Of these patients, 17 consecutive
patients with advanced invasive thymoma, (four patients with
stage III disease, nine with stage IVa disease, and four with stage
IVb disease) including four patients with recurrent tumor, were
enrolled in the study of multimodality therapy including chemo-
therapy, surgery, and/or radiotherapy. In all but three patients,
pathologic diagnosis of thymoma was obtained by thoracotomy,
transthoracic needle biopsy, or fiberoptic bronchoscopic biopsy
before initiation of treatment. Among the patients without pre-
treatment histologic diagnosis, one patient had multiple recur-
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rent pleural tumors after surgical treatment and chemotherapy
for thymoma, and the remaining two had anterior mediastinal
mass suspected invasive thymoma on computed tomography
(CT) that were located at unsuitable places for needle biopsy.
Clinical staging was determined by the medical history and
physical examination, chest radiography, and chest CT.
Other imaging modalities such as magnetic resonance
imaging, echocardiography, or venography were per-
formed when indicated. The staging was based on the
Masaoka staging system.16 All patients gave written in-
formed consent for the study.
The treatment strategy of the multimodality therapy
was as follows: (a) If a tumor of stage III with invasion to
the great vessels or stage IV disease was distinctly dem-
onstrated on diagnostic imaging at the initial staging,
induction chemotherapy was conducted. After three or four
cycles of the chemotherapy, surgical resection was at-
tempted when the residual tumor was found, and consoli-
dation chemotherapy and/or radiotherapy were given. (b)
When stage IV disease was found on operation despite a
clinically earlier stage, surgery for debulking the tumor
was attempted. After that, chemotherapy was administered
as a postsurgical adjuvant treatment, and then radiation
therapy was applied if indicated.
The chemotherapy regimen consisted of cisplatin (20
mg/m2 per day, continuous infusion on days 1 through 4),
doxorubicin (40 mg/m2 intravenously on day 1), and methyl-
prednisolone (1000 mg/day intravenously on days 1 through 4
and 500 mg/day intravenously on days 5 and 6) (CAMP).
Treatment cycles were repeated every 21 to 28 days. Prophy-
lactic granulocyte colony stimulating factor was not routinely
used. Surgery was intended through a median sternotomy in
all patients. Resection was defined as complete (R0) if all
gross disease was removed and if all surgical margins were
free of the tumor. An incomplete resection meant that the
surgical margins were microscopically positive (R1) or that
gross residual tumors (R2) were left at the end of the oper-
ation. Radiation therapy was administered to the mediastinal
or residual tumor areas using opposite anterior and posterior
parallel fields and doses of more than 50 Gy. When malignant
pericardial effusion was noted during the operation, whole
mediastinal irradiation was carried out.
The patients were evaluated with CT for response
after induction chemotherapy and completion of the mul-
timodality treatment. A complete remission (CR) was
defined as the complete disappearance of all objective
evidence of disease on CT for at least 4 weeks. A partial
remission (PR) was defined as a decrease of at least 50%
in the sum of the product of the perpendicular diameter of
measurable lesions for at least 4 weeks. Disease progres-
sion was defined as an increase of at least 25% in tumor
size or new lesions. All other circumstances were classified
as no change (NC).
Survival was measured from the first day of treatment
until death or the last date of the follow-up (March 31, 2004).
The survival curves were calculated according to the Kaplan–
Meier method, and comparisons among the curves were made
by means of the log-rank test. The median follow-up time of
all patients (n  17) was 54 months (range, 2–193 mo), and
median follow-up time of surviving patients (n  14) was 62
months (range, 6–193 mo).
RESULTS
Of the 17 patients, eight were women and nine were
men, ranging in age from 25 to 72 years (median, 51 yr)
(Table 2). Pretreatment pathologic diagnoses were obtained
in 14 patients, and the tumor histology of the remaining three
patients (patients 15–17) was revealed after chemotherapy
and surgical treatment. Histologic types of the thymoma were
B2 tumor in 14 patients and B3 tumor in three patients,
according to the World Health Organization classification.17
All four patients who were diagnosed as having stage III
disease were found to have a tumor with superior vena cava
invasion on diagnostic imaging. Nine patients with stage IVa
disease had pleural tumor dissemination and/or pericardial
effusion, and four with stage IVb disease had pulmonary
metastasis or lymph node involvement.
A summary of treatments and outcomes is listed in
Table 3. CAMP therapy was administered in a neoadjuvant
setting to 14 patients (Figures 1 and 2). One complete
response and 13 partial responses were obtained, with an
overall response rate of 92.9% (95% confidence interval [CI],
66.1–99.8%). After chemotherapy, nine patients underwent
surgical resection of the residual tumor with curative intent.
However, R0 resection was performed in only two patients, R1
resection in one patient, and R2 resection in six patients. Post-
surgical radiotherapy was performed in eight patients. Among
the remaining four patients, one complete responder for CAMP
therapy had no additional treatment. Two partial responders
received radiotherapy because of the unresectable tumor, and
the other one refused further treatment.
Three patients (patients 1, 2, and 11) who were cate-
gorized at the initial staging as having stage I to III disease
were found on operation to have stage IVa disease with
pleural dissemination or malignant pericardial effusion. The
patients underwent resection of the main tumor and extended
TABLE 1. Profile of Patients with Thymoma
Sex
Male 17
Female 21
Age (yr)
Median (range) 57 (25–75)
World Health Organization tumor type
A 2
AB 6
B1 3
B2 22
B3 5
Masaoka stage
I 15
II 4
III 6
IVa 9
IVb 4
Yokoi et al. Journal of Thoracic Oncology • Volume 2, Number 1, January 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer74
thymectomy combined with a partial resection of the pericar-
dium, parietal pleura, and/or lung. Even after the resection,
patients 1 and 11 retained numerous miliary pleural tumors in
the hemithorax, and patient 2, with malignant pericardial
effusion, had a residual mass on the aortic arch. These
patients received four cycles of CAMP therapy after surgery,
and only patient 2 underwent subsequent whole mediastinal
radiation therapy.
TABLE 2. Characteristics of Patients with Advanced Invasive Thymoma
Patient No. Age (yr) Sex Histology Disease Stage Site of Disease
1 40 M B2 IVa Pleural dissemination
2 59 F B2 IVa Pericardial effusion, pericardium, aorta, lung
3 72 M B2 IVa Pericardial effusion, pericardium, SVC, lung
4 63 M B2 IVb Mediastinal lymph nodes, pleural effusion
5 38 F B2 III SVC
6 33 M B2 IVa Pleural dissemination, lung
7 65 F B2 IVb (rec) Pulmonary metastasis, pleural dissemination
8 66 F B2 IVb (rec) Pulmonary metastasis
9 62 F B2 III SVC
10 56 M B3 IVa (rec) Pleural dissemination
11 29 M B2 IVa Pleural dissemination, pericardium, lung
12 49 M B3 IVa Pleural dissemination, pericardium, pulmonary artery
13 51 F B2 III SVC, lung
14 62 F B3 IVa Pleural dissemination
15 25 M B2 IVa (rec) Pleural dissemination
16 29 M B2 IVb Pulmonary metastasis
17 62 F B2 III SVC
Rec, recurrent case; SVC, superior vena cava.
TABLE 3. Summary of Treatments
Patient
No.
Previous
Treatment
Cycles
of
CAMP
Therapy
Response
to CAMP
Therapy
Subsequent
Treatment
Total
Response
Sites of
Tumor
Progression
Progression-
Free
Survival (mo)
Treatment
for Recurrences
Overall
Survival (mo)
1 S (R2) 4 NA CR Pleura 61 S (R0) 193
2 S (R2) 4 NA RT CR 180 180
3 4 PR S (R1),
CAMP  2,
RT
CR Pleura, lung 45 RT 180
4 4 PR S (R2), RT PR Pericardium 11 CT1 13
5 4 PR S (R0), RT CR 169 169
6 2CT2 PR S (R2), RT PR Pleura 17 CT2 18
7 2 PR PR 2 2
8 3 CR CR Pulmonary
metastasis
7 S (R0) 88
9 2 NC S (R2), RT PR Primary site 42 RT 72
10 4 PR RT CR Pleura 32 RT 67
11 S (R2) 4 NA CR Pleura 24 CAMP  2,
S (R0)
56
12 4 PR RT PR 54 54
13 4 PR S (R0) CR 43 43
14 4 PR S (R2), RT CR Pleura 23 CAMP  4 37
15 4 PR PR Pleura 18 CAMP  4,
S (R0)
29
16 4 PR S (R2), RT CR 9 9
17 4 PR S (R2), RT PR 6 6
CR, complete remission; CT1, CDDPVLBBLM; CT2, CPAADMVCRprednisone; NA, not assessable; NC, no change; PR, partial remission; R0, complete resection;
R1, microscopically incomplete resection; R2, macroscopically incomplete resection; RT, radiation therapy; S, surgery.
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After completion of the multimodality therapy, 10 pa-
tients achieved CR and seven achieved PR; the overall
remission rate was 100%. Tumor progression after treatment
was observed in six (60%) of 10 CR patients and in four
(57%) of seven PR patients, with a median progression-free
survival of 24 months (range, 7–61 mo). The remaining six
patients (four CR patients and two PR patients), 35% of the
total population, had no tumor progression six to 180 months
after the initiation of the multimodality therapy.
Treatment for recurrences was performed in all 10
patients. Complete surgical resection for the recurrences with
or without preoperative CAMP therapy was accomplished in
four patients. Patients 1 and 15 underwent an extrapleural
pneumonectomy for pleural dissemination. Patient 8, who
had recurrence after extrapleural pneumonectomy for the
primary tumor, had a wedge lung resection for pulmonary
metastasis, and patient 11 received a partial pleurectomy. For
patients with unresectable recurrent tumors, radiotherapy was
performed in three patients, and chemotherapy was per-
formed in three patients whose tumors were unsuitable for
radiotherapy. Two of the patients treated with chemotherapy
died during the retreatment, one from recurrent tumor and the
other from fulminant rhabdomyolysis.18
The 5- and 10-year overall survival rates of all patients
were both 80.7% (95% CI, 60.9–100%) (Fig. 3). The survival
curves according to stages of disease are shown in Figure 4.
The 10-year survival rates of patients with stage III and stage
IVa disease were 100 and 88.9% (95% CI, 68.4–100%),
respectively. In stage IVb, the 5-year survival rate was 37.5%
(95% CI, 0–93.6%), and only patient 8 survived for more
than 5 years after CAMP therapy and resection for recur-
rence. In the 10 patients with recurrence, the median survival
time and 5-year survival rate after retreatment were 30
months (range, 1–132 mo) and 30.0% (95% CI, 1.6–58.4%),
respectively.
Toxicity of CAMP Therapy and the
Multidisciplinary Treatment
The side effects of CAMP therapy are shown in Table 4.
Seventy-one cycles were administered (median, four cycles;
FIGURE 1. Patient 5 before che-
motherapy. (A) CT scan showing a
large anterior mediastinal tumor
invading the superior vena cava.
(B) Venous phlebogram illustrating
an almost complete obstruction of
the superior vena cava at the level
of the junction of bilateral brachio-
cephalic veins.
FIGURE 2. Patient 5 after four cy-
cles of induction chemotherapy.
(A) CT scan revealing considerable
shrinkage of the tumor. (B) Venous
phlebogram demonstrating the
marked improvement of superior
vena cava obstruction.
FIGURE 3. Overall survival of patients with advanced inva-
sive thymoma who were treated with the multimodality
therapy.
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range, two to eight cycles), and the major adverse effects
were leukopenia and neutropenia. Although 60% of cycles
were associated with grade 3 or 4 neutropenia, almost all
patients in the study received no granulocyte colony stimu-
lating factors or no dose reduction of all three drugs. Treat-
ment delays (median, 1 wk; range, 1–6 wk) were performed
in eight patients because of neutropenia and patients’ wishes.
Chemotherapy-related death occurred in patient 7. She had
multiple pulmonary metastases and pleural recurrences com-
plicated with myasthenia gravis, pure red cell aplasia, and
hypogammaglobulinemia. She died of pneumonia after the
second cycle. Another peculiar complication of tumor lysis
syndrome developed in patient 6, with a huge thymoma of
predominantly lymphocytic type during the first cycle.18
After CAMP therapy and surgical treatment, mild car-
diac dysfunction was observed in two patients (patients 2 and
319) who received whole mediastinal irradiation because of
malignant pericardial effusion. No other severe complications
were encountered.
DISCUSSION
Complete surgical resection is considered essential in
the treatment of thymomas, even for advanced diseases and
recurrences.1–3 Nevertheless, 20 to 40% of patients who
undergo surgery for thymoma receive incomplete resection or
biopsy alone.1–3 Moreover, at the initial staging, some lesions
are regarded as unresectable; these are usually advanced stage
III or stage IV diseases, which are treated with chemotherapy
and/or radiotherapy.6–9
We originated this aggressive multimodality therapy in
February 1988 to improve the survival of patients with
advanced or recurrent thymoma. In our study, eligible pa-
tients were limited to those with stage III lesions with great
vessel invasion, stage IV lesions, or recurrences, because
those tumors are not usually manageable by surgery and
radiotherapy and are associated with unsatisfactory out-
comes.1–5 Our original chemotherapy regimen for invasive
thymoma was designed from single-agent responsiveness for
thymoma, which showed that cisplatin, doxorubicin, and
corticosteroids had been the most active drugs.20 Chemother-
apy was not only administered in a neoadjuvant setting but
also in a postsurgical adjuvant setting, because the initial
stagings have not always been accurately estimated, even
with CT and magnetic resonance imaging.
Neoadjuvant chemotherapy for invasive thymoma has
been attempted in the treatment of locally advanced diseases
because of the effectiveness of combination chemotherapy.10–15
The chemotherapy regimens administered have been diverse,
but almost all have included cisplatin and doxorubicin/epiru-
bicin. The reported response rates have been documented to
be 69 to 100%, and some patients receiving the treatment
have had complete histologic remission. After induction che-
motherapy for advanced tumors, the complete resection rates
were around 70%. Of patients receiving the multimodality
therapy using induction chemotherapy for locally advanced
invasive thymoma, 5-year overall survival rates were re-
ported to be between 55 and 95%,13–15 because the study
populations and treatment strategies were different.
In our 14 patients with neoadjuvant therapy, the re-
sponse rate of CAMP therapy was 92.9%, which was better
than or comparable with those of previous reports.6–15 How-
ever, only two patients underwent complete resection, and
seven underwent incomplete resection. The other tumors
were interpreted as being unresectable after induction che-
motherapy. Even after postsurgical radiotherapy, four pa-
tients without complete resection remained in PR, and two of
them had a short survival. Our low complete resection rate is
considered to be a result of the far advancement of the
tumors: 13 of 17 patients had stage IV disease and/or recur-
rent tumors. Furthermore, CT was still incapable of predict-
ing the possibility of performing a radical excision of the
tumors after induction chemotherapy.
Patients undergoing incomplete resection or biopsy
have been reported to show a significantly shorter survival
than those with complete resection.1–3 Blumberg et al.2 re-
ported that survival rates in patients with partial resection had
been documented at 70 and 28% for 5 and 10 years, and 38
and 24% for biopsy, respectively. All three of our patients
who had stage IV disease and were treated with surgery and
then adjuvant chemotherapy with or without radiotherapy had
distinct residual tumors after the operation. After the adjuvant
therapy, two patients had pleural recurrences, but only after
disease-free intervals of more than 5 and 2 years, respec-
tively. In the remaining patient, postoperative CAMP therapy
FIGURE 4. Survival according to the Masaoka staging sys-
tem. In univariate analysis, there was a significant difference
between stage IVa and stage IVb disease (p  0.036), but
there were no significant differences between stage III and
stage IVa disease (p  0.564) and stage III and IVb disease
(p  0.123).
TABLE 4. Toxic Effects of Cisplatin, Doxorubicin, and
Methylprednisolone Therapy
NCI-CTC
grade (%) 0 1 2 3 4 5
Leukocytes 14 12 39 27 8
Neutrophils 10 9 21 34 26
Hemoglobin 75 12 11 3
Platelets 55 36 6 3
Nausea/vomiting 31 26 36 5 1
Infection 92 3 3 1 1
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and irradiation have managed the residual disease for more
than 10 years. From our available data of those patients with
the adjuvant therapy, we think that aggressive postsurgical
treatment including chemotherapy is useful to cure or control
residual lesions in patients with incomplete resection of the
primary tumors, effectively maintaining their quality of life
for a longer period.
In the multimodality therapy, some complications were
noted. With chemotherapy, fatal infection and tumor lysis
syndrome were observed in peculiar patients with parathymic
syndrome of hypogammaglobulinemia and extensive lym-
phocytic thymoma associated with peripheral blood T-cell
lymphocytosis,18 respectively. No mortality was encountered
in surgical treatment. After radiation therapy, mild cardiac
dysfunction was observed in two patients who had whole
mediastinal irradiation for malignant pericardial effusion.19
This complication is probably caused by doxorubicin and
radiation affecting the heart muscle synergistically. On the
whole, we think that this multimodality therapy is tolerable as
long as attention is paid to any peculiar conditions.
For the recurrent tumors in six patients exhibiting CR,
we aggressively performed retreatment. Extrapleural pneu-
monectomy or partial pleurectomy was carried out in three
patients with pleural recurrences, pulmonary metastasectomy
was carried out in one patient who was in a postpneumonec-
tomy state, and repetitive radiotherapy was carried out in two
patients with mediastinal or diaphragmatic local recurrences.
All six patients are still in good general condition 37 to 193
months after the initial treatment. From our experience, we
consider that aggressive retreatment for recurrences even
after the multimodality therapy is very important for control-
ling disease and maintaining good quality of life, as previous
reports have also advocated.21,22
The treatment of advanced thymoma is still controver-
sial. However, investigators have recently advocated the
necessity of multimodal approaches to therapy that introduce
the enhancement of tumor resectability, cure rate, and/or
long-term disease control.10–15 In studies of such multidisci-
plinary treatment, Shin et al.12 and Kim et al.15 have reported
excellent results in the survival of patients with stage III or IV
thymoma. Their study protocol was considered a precise
long-term treatment, which consisted of induction chemo-
therapy (cisplatin, doxorubicin, cyclophosphamide, and pred-
nisone), surgical resection, postoperative radiotherapy, and
consolidation chemotherapy. From our study, we also recog-
nize the importance of postsurgical adjuvant therapy for
patients with advanced disease and/or incomplete resection as
well as the importance of retreatment for recurrences after the
multimodality therapy. Future studies on the treatment of
advanced invasive thymoma should follow a meticulous
scheme of a primary multidisciplinary approach to therapy
and retreatment of recurrences.
In conclusion, CAMP therapy was highly effective for
invasive thymomas. Although this study was limited by its
small number of patients and its nonrandomized clinical trial
design, we believe that the multimodality therapy containing
this chemotherapy is justifiable for the initial treatment of
patients with advanced thymoma such as stage III disease
with major vessel invasion, stage IV disease, and recurrence.
Further studies are warranted to determine the optimal treat-
ment strategy.
REFERENCES
1. Nakahara K, Ohno K, Hashimoto J, et al. Thymoma: results with
complete resection and adjuvant postoperative irradiation in 141 con-
secutive patients. J Thorac Cardiovasc Surg 1988;95:1041–1047.
2. Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate
analysis of factors predicting survival. Ann Thorac Surg 1995; 60:
908–914.
3. Regnard JF, Magdeleinat P, Dromer C, et al. Prognostic factors and
long-term results after thymoma resection: a series of 307 patients.
J Thorac Cardiovasc Surg 1996;112:376–384.
4. Ichinose Y, Ohta M, Yano T, Yokoyama H, Asoh H, Hata K. Treatment
of invasive thymoma with pleural dissemination. J Surg Oncol 1993;54:
180–183.
5. Okumura M, Miyoshi S, Takeuchi Y, et al. Results of surgical treatment
of thymomas with special reference to the involved organs. J Thorac
Cardiovasc Surg 1999;117:605–613.
6. Fornasiero A, Daniele O, Ghiotto C, Clerico M, Sahmoud T, van
Zandwijk N. Chemotherapy for invasive thymoma. A 13-year experi-
ence. Cancer 1991;68:30–33.
7. Giaccone G, Ardizzoni A, Kirkpatrick A, et al. Cisplatin and etoposide
combination chemotherapy for locally advanced or metastatic thymoma:
a phase II study of the European Organization for Research and Treat-
ment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996;
14:814–820.
8. Loehrer PJ, Sr, Chen M, Kim KM, et al. Cisplatin, doxorubicin, and
cyclophosphamide plus thoracic radiation therapy for limited-stage un-
resectable thymoma: an intergroup trial. J Clin Oncol 1997;15:3093–
3099.
9. Highley MS, Underhill CR, Parnis FX, et al. Treatment of invasive
thymoma with single-agent ifosfamide. J Clin Oncol 1999;17:2737–
2744.
10. Rea F, Sartori F, Loy M, et al. Chemotherapy and operation for invasive
thymoma. J Thorac Cardiovasc Surg 1993;106:543–549.
11. Venuta F, Rendina EA, Pescarmona EO, et al. Multimodality treatment
of thymoma: a prospective study. Ann Thorac Surg 1997;64:1585–1592.
12. Shin DM, Walsh GL, Komaki R, et al. A multidisciplinary approach to
therapy for unresectable malignant thymoma. Ann Intern Med 1998;129:
100–104.
13. Rea F, Marulli G, Girardi R, et al. Long-term survival and prognostic
factors in thymic epithelial tumours. Eur J Cardiothorac Surg 2004;26:
412–418.
14. Venuta F, Rendina EA, Longo F, et al. Long-term outcome after
multimodality treatment for stage III thymic tumors. Ann Thorac Surg
2003;76:1866–1872.
15. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisci-
plinary approach with induction chemotherapy, followed by surgical
resection, radiation therapy, and consolidation chemotherapy for unresect-
able malignant thymomas: final report. Lung Cancer 2004;44:369–379.
16. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of
thymomas with special reference to their clinical stages. Cancer 1981;
48:2485–2492.
17. Rosai J, Sobin LH. Histological Typing of Tumours of the Thymus.
International Histological Classification of Tumours, 2nd ed. New York:
Springer, 1999.
18. Yokoi K, Miyazawa N, Kano Y, et al. Tumor lysis syndrome in invasive
thymoma with peripheral blood T-cell lymphocytosis. Am J Clin Oncol
1997;20:86–89.
19. Yokoi K, Miyazawa N, Mori K, et al. Invasive thymoma with intracaval
growth into the right atrium. Ann Thorac Surg 1992;53:507–509.
20. Hu E, Levine J. Chemotherapy of malignant thymoma. Case report and
review of the literature. Cancer 1986;57:1101–1104.
21. Ruffini E, Mancuso M, Oliaro A, et al. Recurrence of thymoma: analysis
of clinicopathologic features, treatment, and outcome. J Thorac Cardio-
vasc Surg 1997;113:55–63.
22. Regnard JF, Zinzindohoue F, Magdeleinat P, Guibert L, Spaggiari L,
Levasseur P. Results of re-resection for recurrent thymomas. Ann Tho-
rac Surg 1997;64:1593–1598.
Yokoi et al. Journal of Thoracic Oncology • Volume 2, Number 1, January 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer78
